10 June 2024, Mumbai: A pivotal symposium organised today by Médecins Sans Frontières (MSF)/Doctors Without Borders brought together a diverse coalition of experts and stakeholders to forge actionable strategies against Drug-Resistant Tuberculosis (DRTB). This crucial gathering aimed to highlight the key successes and challenges in the battle against TB, with an emphasis on enhancing the … Read more
MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics. Recent deal offering controlled generics access in limited countries does not go far enough. Delhi/Cape Town/Geneva, 18 July, 2023 – As Johnson & Johnson’s (J&J) 20-year … Read more
Christophe Perrin, TB advocacy pharmacist, MSF Access Campaign “Today’s announcement by the Stop TB Partnership/Global Drug Facility about a deal with pharmaceutical corporation Johnson & Johnson (J&J), for access to affordable generic versions of the lifesaving tuberculosis (TB) drug bedaquiline, offers a short-term solution for low- and middle-income countries — but the deal remains just a … Read more
Mumbai, 23 March 2023 – Today, the 2019 patent challenge by two tuberculosis (TB) survivors, Nandita Venkatesan and Phumeza Tisile, was successful: the Indian Patent Office rejected the US pharmaceutical corporation Johnson & Johnson’s (J&J) attempt to extend its monopoly in India on the TB drug bedaquiline beyond the primary patent’s expiry this July. Médecins … Read more
Delhi, 22 March 2023 – Médecins Sans Frontières/Doctors Without Borders (MSF) called on governments and donors today to speed up access to new, shorter, safer and more effective treatments* for drug-resistant tuberculosis (DR-TB), as well as the diagnostic tests needed to implement the new treatment regimens. MSF joined the World Health Organization (WHO) and other … Read more
The World Health Organization (WHO) released today the 2022 edition of its Global Tuberculosis (TB) Report, featuring data on the TB response and trends in 215 countries and areas. Among the alarming trends from 2021, there is an increase in the estimated incidence of TB for the first time in two decades, including for the more difficult … Read more
LONDON – TB-PRACTECAL, a clinical trial led by Doctors Without Borders/Médecins Sans Frontières (MSF), has found that a new, all-oral, six-month treatment regimen is safer and more effective at treating rifampicin-resistant tuberculosis (RR-TB) [1] than the currently accepted standard of care. These results signal the start of a new chapter for people with drug-resistant (DR)-TB, who … Read more
BOSTON/PARIS — Hundreds of patient volunteers from four continents have enrolled in a trial that aims to find safer, shorter, and effective treatments for multidrug-resistant tuberculosis (MDR-TB), an airborne, infectious disease that has grown resistant to standard medications. A group of scientists and clinicians led by Doctors Without Borders/Médecins Sans Frontières (MSF), Partners In Health (PIH), and Interactive … Read more